Über uns
Firmenpräsentation
Milestones
Presse
Forschung & Entwicklung
5-Aminolävulinsäure
Therapiebereiche
Aktinische Keratose
Glioblastoma
Produkte
Karriere
Kontakt
Über uns
Firmenpräsentation
Milestones
Presse
Forschung & Entwicklung
5-Aminolävulinsäure
Therapiebereiche
Aktinische Keratose
Glioblastoma
Produkte
Karriere
Kontakt
News Archiv
Phase 3 Study of 5-ALA in Meningioma Surgery Meets Primary Endpoint
Marketing Authorisation for Gliolan
®
granted in Jordan
SBI Pharma to succeed Marketing Authorization of “Alabel® Oral 1.5g” from Nobelpharma
First Patient Enrolled in OVA-302 Study After FDA Orphan Designation for Gleolan®
photonamic GmbH & Co. KG successfully obtains ManufacturingLicense under GMP
NX Development Corp. Is Granted Orphan-Drug Designation Status by US FDA forGleolan® in Ovarian and Related Cancers
SBI ALApromo GmbH Announces Registration of 5-aminolevulinic Acid Phosphate Containing Cosmetic, Kiyomi Skin, in Saudi Arabia
US FDA Medical Device Registration of Aladuck405/II
NutraIngredients-Awardsgranted for clinical study project with the food supplement 5-ALA + SFC as animmune system enhancer for COVID-19 vaccines
Photonamic and PhotonicsHealthcare strengthen collaboration after successful clinical pilot study ofoxygen measurement technology
Photonamic and Lumeda Enter into Collaboration for a Clinical Study with Photodynamic Therapy (“PDT”) in the Field of Non-Small Cell Lung Cancer (NSCLC)
FerroSens’ FIDscreen prototype devices successfully applied in clinicalstudy during blood donation
First-in-Human Study for New Application of Photodynamic Therapy with 5-Aminolevulinic Acid for Extracorporeal Photopheresis
First Patient Enrolled in Phase 2 Trial with Interstitial Photodynamic Therapy
Brustkrebsoperionen mit 5-ALA, Artikel aus Pinneberger Tageblatt
Results of Phase II Trial for Breast Cancer Surgery Published in Breast Cancer Research
Pinneberger Pharmafirma arbeitet an Urintest zur Krebsfrüherkennung
First Patient Enrolled in Pivotal Phase 3 Trial for Breast Conserving Surgery
Artikel aus Pinneberger Tageblatt, April 2021:
Pinneberger Pharma-Unternehmen: Medikament gegen Covid verträglich / Wirksamkeit deutet sich an.
photonamic Acquires Majority Stake in FerroSens
Research with 5-ALA phosphate and Sodium Ferrous Citrate in COVID-19 patients
Start of Phase II Clinical Trial using 5-ALA by the University of Oxford and SBI Pharmaceuticals
Medexus Announces Expanded Availability of Gleolan® in Canada
Case Reports on Treatment with 5-ALA Phosphate for Patients with New Coronavirus Infection (COVID-19)
NX DEVELOPMENT CORP. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan®
NX DEVELOPMENT CORP IN THE USA LAUNCHES GLEOLAN™ (AMINOLEVULINIC ACID HCL) MENINGIOMA PHASE III CLINICAL TRIAL
